Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garth W Strohbehn

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 11, 2023
New strategies for dose optimization in oncology: insights from targeted small-molecule therapies for metastatic or advanced non-small cell lung cancerGarth W Strohbehn
Nature Reviews. Clinical Oncology|January 5, 2024
'Contribution of component' and the perioperative immune-checkpoint inhibitor precedentGarth W Strohbehn, Bishal Gyawali
JAMA Oncology|November 16, 2023
Immunotherapy in Prepatients-Preventing or Promoting a Malignant Transformation?Bishal Gyawali, Garth W Strohbehn
JCO Precision Oncology|February 1, 2022
Precision and Accuracy in the Brave New World of Basket TrialsGarth W Strohbehn, Mark J Ratain
Clinical Pharmacology and Therapeutics|April 6, 2019
Immunotherapy and the A2A Adenosine Receptor: A Confounding BrewGarth W Strohbehn, Mark J Ratain
European Journal of Cancer (Oxford, England : 1990)|October 8, 2023
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?Mark J Ratain, Garth W Strohbehn
JTO Clinical and Research Reports|July 3, 2026
Ivonescimab: The Next United States Food and Drug Administration Project Optimus Flashpoint?Garth W Strohbehn, Mark J Ratain
The Lancet. Oncology|July 29, 2019
Palbociclib: a new partner for cetuximab?Garth W Strohbehn, Everett E Vokes
Clinical Pharmacology and Therapeutics|April 8, 2022
Lorlatinib Exposed: A Far From Optimal DoseGarth W Strohbehn, Mark J Ratain
The Oncologist|December 25, 2019
Mistaking the Trees for the Forest?Garth W Strohbehn, Christopher K Daugherty
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Clinical Advances in Hematology & Oncology : H&O|April 11, 2023
New strategies for dose optimization in oncology: insights from targeted small-molecule therapies for metastatic or advanced non-small cell lung cancerGarth W Strohbehn
Nature Reviews. Clinical Oncology|January 5, 2024
'Contribution of component' and the perioperative immune-checkpoint inhibitor precedentGarth W Strohbehn, Bishal Gyawali
JAMA Oncology|November 16, 2023
Immunotherapy in Prepatients-Preventing or Promoting a Malignant Transformation?Bishal Gyawali, Garth W Strohbehn
JCO Precision Oncology|February 1, 2022
Precision and Accuracy in the Brave New World of Basket TrialsGarth W Strohbehn, Mark J Ratain
Clinical Pharmacology and Therapeutics|April 6, 2019
Immunotherapy and the A2A Adenosine Receptor: A Confounding BrewGarth W Strohbehn, Mark J Ratain
European Journal of Cancer (Oxford, England : 1990)|October 8, 2023
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?Mark J Ratain, Garth W Strohbehn
JTO Clinical and Research Reports|July 3, 2026
Ivonescimab: The Next United States Food and Drug Administration Project Optimus Flashpoint?Garth W Strohbehn, Mark J Ratain
The Lancet. Oncology|July 29, 2019
Palbociclib: a new partner for cetuximab?Garth W Strohbehn, Everett E Vokes
Clinical Pharmacology and Therapeutics|April 8, 2022
Lorlatinib Exposed: A Far From Optimal DoseGarth W Strohbehn, Mark J Ratain
The Oncologist|December 25, 2019
Mistaking the Trees for the Forest?Garth W Strohbehn, Christopher K Daugherty
Pageof 7